NRG Therapeutics Presents Data on Lead Clinical Asset NRG5051 Confirming Novel Disease-Modifying Approach to ALS

Poster presentation at the ALS Association’s ALS Nexus…
24 August 2026/by Webadm

NRG Therapeutics Announces the Appointment of Claus Sundgreen M.D. as Chief Medical Officer

Stevenage, UK, 3 August 2026 - NRG Therapeutics Ltd. (“NRG”),…
3 August 2026/by Webadm

NRG Therapeutics Announces First Participants Dosed in its First-in-Human Phase 1 Clinical Trial of NRG5051 Which is Being Developed as a Disease-modifying Treatment for ALS/MND and Parkinson’s

Stevenage, UK, 8 January 2026 - NRG Therapeutics Ltd. (“NRG”),…
8 January 2026/by Webadm

NRG Therapeutics Announces Further Expansion with the Appointment of Paul Thompson as Chief Development Officer

Stevenage, UK, 1 December 2025 - NRG Therapeutics Ltd. (“NRG”),…
1 December 2025/by Webadm

NRG Therapeutics Announces Senior Appointments as it Advances NRG5051 Towards First-in-Human Clinical Studies

Stevenage, UK, 23 October 2025 - NRG Therapeutics Ltd. (“NRG”),…
23 October 2025/by Webadm

NRG Therapeutics Announces Oversubscribed £50m ($67m) Series B Financing to Deliver Clinical Data in Parkinson’s and Proof of Concept in ALS/MND

Oversubscribed £50m Series B led by SV Health Investors’…
8 September 2025/by Webadm

NRG Therapeutics Selects First Development Candidate, NRG5051, and Secures Grant from The Michael J. Fox Foundation for Development of mPTP Inhibitors to Treat Neurodegenerative Diseases

First development candidate selected, NRG5051, with potential…
31 October 2024/by Webadm

NRG Therapeutics Awarded Grant Funding from Target ALS to Support the Development of mPTP Inhibitors as Novel Treatments for ALS/MND

Stevenage, UK, 5 August 2024 - NRG Therapeutics, Ltd., an innovative…
5 September 2024/by Webadm

NRG Therapeutics Appoints Dr Jonathan Savidge as Independent Chair

Stevenage, UK, 26 April 2023 - NRG Therapeutics, Ltd., an innovative…
26 April 2023/by Webadm